Download PDF
Semin Thromb Hemost 2022; 48(08): 955-970
DOI: 10.1055/s-0042-1753485
Review Article

A Historical Perspective on the Reversal of Anticoagulants

Brittany Salter
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Mark Crowther
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

There has been a landmark shift in the last several decades in the management and prevention of thromboembolic events. From the discovery of parenteral and oral agents requiring frequent monitoring as early as 1914, to the development of direct oral anticoagulants (DOACs) that do not require monitoring or dose adjustment in the late 20th century, great advances have been achieved. Despite the advent of these newer agents, bleeding continues to be a key complication, affecting 2 to 4% of DOAC-treated patients per year. Bleeding is associated with substantial morbidity and mortality. Although specific reversal agents for DOACs have lagged the release of these agents, idarucizumab and andexanet alfa are now available as antagonists. However, the efficacy of these reversal agents is uncertain, and complications, including thrombosis, have not been adequately explored. As such, guidelines continue to advise the use of nonspecific prohemostatic agents for patients requiring reversal of the anticoagulant effect of these drugs. As the indications for DOACs and the overall prevalence of their use expand, there is an unmet need for further studies to determine the efficacy of specific compared with nonspecific pro-hemostatic reversal agents. In this review, we will discuss the evidence behind specific and nonspecific reversal agents for both parenteral and oral anticoagulants.

Keywords

anticoagulation - DOACs - VKA - andexanet alfa - ciraparantag - idarucizumab - reversal


Publication History

Article published online:
02 September 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Franchini M, Liumbruno GM, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfus 2016; 14 (02) 175-184
    PubMedGoogle Scholar
  • 2 Carlson B. Declaring war on warfarin misdosing. Biotechnol Healthc 2008; 5 (02) 54-55
    PubMedGoogle Scholar
  • 3 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 4 Zehnder J, Price E, Jin J. Controversies in heparin monitoring. Am J Hematol 2012; 87 (Suppl. 01) S137-S140
    CrossrefPubMedGoogle Scholar
  • 5 Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111 (10) 4871-4879
    CrossrefPubMedGoogle Scholar
  • 6 Hirsh J, Anand SS, Halperin JL, Fuster V. American Heart Association. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103 (24) 2994-3018
    Google Scholar
  • 7 Hirsh J. Orgaran-extending the frontiers of venous thrombosis prophylaxis-summary and conclusions. Haemostasis 1992; 22 (02) 112
    PubMedGoogle Scholar
  • 8 Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992; 22 (02) 73-84
    PubMedGoogle Scholar
  • 9 Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95 (06) 967-981
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kinra P, Kumar H. Recombinant factor VIIA. Med J Armed Forces India 2009; 65 (01) 59-61
    CrossrefPubMedGoogle Scholar
  • 11 Lauritzen B, Hedner U, Johansen PB, Tranholm M, Ezban M. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J Thromb Haemost 2008; 6 (05) 804-811
    CrossrefPubMedGoogle Scholar
  • 12 Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82 (04) 257-258
    CrossrefPubMedGoogle Scholar
  • 13 MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005; 45 (09) 1434-1442
    CrossrefPubMedGoogle Scholar
  • 14 Wang CH, Chen YC, Tsao CW, Yang SS. Dalteparin-associated catastrophic retroperitoneal hematoma successfully treated with recombinant factor VIIa. Int Urol Nephrol 2012; 44 (04) 1091-1095
    CrossrefPubMedGoogle Scholar
  • 15 Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18 (06) 547-553
    CrossrefPubMedGoogle Scholar
  • 16 Schmahl KS, Ganjoo AK, Harloff MG. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis. J Cardiothorac Vasc Anesth 1997; 11 (02) 262-263
    CrossrefPubMedGoogle Scholar
  • 17 Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100 (02) 350-355
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl): 141S-159S
    Google Scholar
  • 19 Pai M, Crowther MA. Neutralization of heparin activity. Handb Exp Pharmacol 2012; (207) 265-277
    CrossrefPubMedGoogle Scholar
  • 20 Patel AA, White CM, Coleman CI. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. Conn Med 2007; 71 (02) 93-95
    PubMedGoogle Scholar
  • 21 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): e24S-e43S
    Google Scholar
  • 22 van Veen JJ, Maclean RM, Hampton KK. et al. Protamine reversal of low molecular weight heparin: clinically effective?. Blood Coagul Fibrinolysis 2011; 22 (07) 565-570
    CrossrefPubMedGoogle Scholar
  • 23 Crowther MA, Berry LR, Monagle PT, Chan AKC. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116 (01) 178-186
    CrossrefPubMedGoogle Scholar
  • 24 Lu C, Crowther MA, Mithoowani S. Management of intentional overdose of low-molecular-weight heparin. CMAJ 2022; 194 (04) E122-E125
    CrossrefPubMedGoogle Scholar
  • 25 Kalathottukaren MT, Creagh AL, Abbina S. et al. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. Blood Adv 2018; 2 (16) 2104-2114
    CrossrefPubMedGoogle Scholar
  • 26 Powell J, Taylor J, Garland SG. Andexanet alfa: a novel factor Xa inhibitor reversal agent. Ann Pharmacother 2019; 53 (09) 940-946
    CrossrefPubMedGoogle Scholar
  • 27 Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med 2017; 8: 141-149
    CrossrefPubMedGoogle Scholar
  • 28 Siddiqui F, Tafur A, Bontekoe E. et al. Assay-based differentiation in the neutralization profile of unfractionated heparin, enoxaparin, and fondaparinux by andexanet alfa. Clin Appl Thromb Hemost 2020; 26: 10760296 19895120
    CrossrefPubMedGoogle Scholar
  • 29 Montalescot G, Zapol WM, Carvalho A, Robinson DR, Torres A, Lowenstein E. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep. Circulation 1990; 82 (05) 1754-1764
    CrossrefPubMedGoogle Scholar
  • 30 Carpenter E, Singh D, Dietrich E, Gums J. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf 2019; 10: 20420986 19888133
    CrossrefPubMedGoogle Scholar
  • 31 Lu G, Lin J, Curnutte JT, Conley PB. Reversal of heparin-induced anticoagulation by andexanet alfa, a universal antidote for factor Xa inhibitors. Blood 2015; 126 (23) 2329
    CrossrefPubMedGoogle Scholar
  • 32 van Haaps TF, Benz AP, Xu L. et al. Andexant Alfa for acut bleeding during treatment with enoxaparin. J Am Coll Cardiol 2021; 77 (18, Suppl_1): 1856
    CrossrefPubMedGoogle Scholar
  • 33 Ansell JE, Bakhru SH, Laulicht BE. et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017; 117 (02) 238-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Ansell J, Laulicht BE, Bakhru SH. et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood 2021; 137 (01) 115-125
    CrossrefPubMedGoogle Scholar
  • 35 Ansell JE, Bakhru SH, Laulicht BE. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371 (22) 2141-2142
    CrossrefPubMedGoogle Scholar
  • 36 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 160S-198S
    CrossrefPubMedGoogle Scholar
  • 37 Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 1978; 15 (01) 19-26
    PubMedGoogle Scholar
  • 38 O'Reilly RA. Warfarin metabolism and drug-drug interactions. Adv Exp Med Biol 1987; 214: 205-212
    PubMedGoogle Scholar
  • 39 Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc Bayl Univ Med Cent 2001; 14 (03) 305-306
    CrossrefPubMedGoogle Scholar
  • 40 Palareti G, Leali N, Coccheri S. et al; Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348 (9025): 423-428
    CrossrefPubMedGoogle Scholar
  • 41 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167 (13) 1414-1419
    CrossrefPubMedGoogle Scholar
  • 42 Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135 (06) 393-400
    CrossrefPubMedGoogle Scholar
  • 43 Aguilar MI, Hart RG, Kase CS. et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82 (01) 82-92
    CrossrefPubMedGoogle Scholar
  • 44 Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg 2012; 116 (03) 491-497
    CrossrefPubMedGoogle Scholar
  • 45 Sheikh-Taha M, Crawley RM. Efficacy and safety of activated prothrombin complex concentrate for the reversal of vitamin K antagonist major bleeding. Sci Rep 2022; 12 (01) 1814
    CrossrefPubMedGoogle Scholar
  • 46 Wójcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009; 2 (04) 217-225
    CrossrefPubMedGoogle Scholar
  • 47 Rowe AS, Dietrich SK, Phillips JW, Foster KE, Canter JR. Activated prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for vitamin K-antagonist reversal. Crit Care Med 2018; 46 (06) 943-948
    CrossrefPubMedGoogle Scholar
  • 48 Dentali F, Marchesi C, Giorgi Pierfranceschi M. et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106 (03) 429-438
    PubMedGoogle Scholar
  • 49 Milling Jr TJ, Refaai MA, Goldstein JN. et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med 2016; 67 (01) 96-105.e5
    CrossrefPubMedGoogle Scholar
  • 50 Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9 (08) 741-748
    CrossrefPubMedGoogle Scholar
  • 51 Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8 (02) 83-90
    CrossrefPubMedGoogle Scholar
  • 52 Mayer SA, Brun NC, Begtrup K. et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358 (20) 2127-2137
    CrossrefPubMedGoogle Scholar
  • 53 Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137 (11) 884-888
    CrossrefPubMedGoogle Scholar
  • 54 Robinson MT, Rabinstein AA, Meschia JF, Freeman WD. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke 2010; 41 (07) 1459-1463
    CrossrefPubMedGoogle Scholar
  • 55 Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116 (05) 693-701
    CrossrefPubMedGoogle Scholar
  • 56 Diringer MN, Skolnick BE, Mayer SA. et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010; 41 (01) 48-53
    CrossrefPubMedGoogle Scholar
  • 57 Chai-Adisaksopha C, Hillis C, Siegal DM. et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016; 116 (05) 879-890
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Chapman SA, Irwin ED, Abou-Karam NM. et al. Comparison of 3-factor prothrombin complex concentrate and low-dose recombinant factor VIIa for warfarin reversal. World J Emerg Surg 2014; 9 (01) 27
    CrossrefPubMedGoogle Scholar
  • 59 Martin DT, Barton CA, Dodgion C, Schreiber M. Emergent reversal of vitamin K antagonists: addressing all the factors. Am J Surg 2016; 211 (05) 919-925
    CrossrefPubMedGoogle Scholar
  • 60 Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006; 166 (04) 391-397
    PubMedGoogle Scholar
  • 61 Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115 (01) 145-149
    CrossrefPubMedGoogle Scholar
  • 62 Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21 (01) 37-48
    CrossrefPubMedGoogle Scholar
  • 63 Crowther MA, Garcia D, Ageno W. et al. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost 2010; 104 (01) 118-121
    PubMedGoogle Scholar
  • 64 Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res 2004; 113 (3–4): 205-209
    CrossrefPubMedGoogle Scholar
  • 65 Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163 (20) 2469-2473
    CrossrefPubMedGoogle Scholar
  • 66 Farrow GS, Delate T, McNeil K. et al. Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio > 10. J Thromb Haemost 2020; 18 (05) 1133-1140
    CrossrefPubMedGoogle Scholar
  • 67 Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120 (20) 2006-2011
    CrossrefPubMedGoogle Scholar
  • 68 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106 (20) 2550-2554
    CrossrefPubMedGoogle Scholar
  • 69 Bijsterveld NR, Vink R, van Aken BE. et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124 (05) 653-658
    CrossrefPubMedGoogle Scholar
  • 70 Lisman T, Bijsterveld NR, Adelmeijer J. et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1 (11) 2368-2373
    CrossrefPubMedGoogle Scholar
  • 71 Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91 (03) 531-537
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14 (06) 557-562
    CrossrefPubMedGoogle Scholar
  • 73 Luporsi P, Chopard R, Janin S. et al. Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 2011; 13 (02) 93-98
    CrossrefPubMedGoogle Scholar
  • 74 Desmurs-Clavel H, Huchon C, Chatard B, Negrier C, Dargaud Y. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123 (05) 796-798
    CrossrefPubMedGoogle Scholar
  • 75 Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood 2019; 133 (05) 425-435
    CrossrefPubMedGoogle Scholar
  • 76 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (03) 292-303
    CrossrefPubMedGoogle Scholar
  • 77 Gosselin R, Hawes E, Moll S, Adcock D. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol 2014; 141 (02) 262-267
    CrossrefPubMedGoogle Scholar
  • 78 Lindahl TL, Baghaei F, Blixter IF. et al; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105 (02) 371-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Pernod G, Albaladejo P, Godier A. et al; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013; 106 (6–7): 382-393
    CrossrefPubMedGoogle Scholar
  • 80 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    Google Scholar
  • 81 Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46 (04) e10
    CrossrefPubMedGoogle Scholar
  • 82 Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366 (09) 864-866
    CrossrefPubMedGoogle Scholar
  • 83 Chen BC, Viny AD, Garlich FM. et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 2012; 50 (09) 854-857
    CrossrefPubMedGoogle Scholar
  • 84 Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012; 10 (02) 160-163
    CrossrefPubMedGoogle Scholar
  • 85 Béné J, Saïd W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother 2012; 46 (06) e14-e14
    CrossrefPubMedGoogle Scholar
  • 86 Sipahi I, Celik S, Tozun N. A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med 2014; 174 (01) 150-151
    CrossrefPubMedGoogle Scholar
  • 87 Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol 2015; 35 (08) 1736-1745
    CrossrefPubMedGoogle Scholar
  • 88 Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49 (04) 259-268
    CrossrefPubMedGoogle Scholar
  • 89 Singh T, Maw TT, Henry BL. et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013; 8 (09) 1533-1539
    CrossrefPubMedGoogle Scholar
  • 90 Grottke O, van Ryn J, Spronk HMH, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014; 18 (01) R27
    PubMedGoogle Scholar
  • 91 Pragst I, Zeitler SH, Doerr B. et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10 (09) 1841-1848
    CrossrefPubMedGoogle Scholar
  • 92 Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10 (09) 1830-1840
    CrossrefPubMedGoogle Scholar
  • 93 Hoffman M, Volovyk Z, Monroe DM. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. Anesthesiology 2015; 122 (02) 353-362
    CrossrefPubMedGoogle Scholar
  • 94 Honickel M, Braunschweig T, van Ryn J. et al. Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model. Anesthesiology 2015; 123 (06) 1350-1361
    CrossrefPubMedGoogle Scholar
  • 95 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42 (12) 3594-3599
    CrossrefPubMedGoogle Scholar
  • 96 van Ryn J, Schurer J, Kink-Eiband M, Clemens A. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 2014; 120 (06) 1429-1440
    CrossrefPubMedGoogle Scholar
  • 97 Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113 (04) 728-740
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Honickel M, Braunschweig T, Rossaint R, Stoppe C, Ten Cate H, Grottke O. Reversing dabigatran anticoagulation with prothrombin complex concentrate versus idarucizumab as part of multimodal hemostatic intervention in an animal model of polytrauma. Anesthesiology 2017; 127 (05) 852-861
    CrossrefPubMedGoogle Scholar
  • 99 Herzog E, Kaspereit FJ, Krege W. et al. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thromb Res 2014; 134 (03) 729-736
    CrossrefPubMedGoogle Scholar
  • 100 Honickel M, Maron B, van Ryn J. et al. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thromb Haemost 2016; 115 (02) 271-284
    Article in Thieme ConnectPubMedGoogle Scholar
  • 101 van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;93(Suppl 1)
    PubMedGoogle Scholar
  • 102 Arellano-Rodrigo E, Lopez-Vilchez I, Galan AM. et al. Coagulation factor concentrates fail to restore alterations in fibrin formation caused by rivaroxaban or dabigatran in studies with flowing blood from treated healthy volunteers. Transfus Med Rev 2015; 29 (04) 242-249
    CrossrefPubMedGoogle Scholar
  • 103 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
    CrossrefPubMedGoogle Scholar
  • 104 Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108 (02) 217-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 105 Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013; 35 (02) 222-224
    CrossrefPubMedGoogle Scholar
  • 106 Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014; 111 (05) 989-995
    Article in Thieme ConnectPubMedGoogle Scholar
  • 107 Schulman S, Ritchie B, Nahirniak S. et al; Study investigators. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study. Thromb Res 2017; 152: 44-48
    CrossrefPubMedGoogle Scholar
  • 108 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113 (05) 943-951
    Article in Thieme ConnectPubMedGoogle Scholar
  • 109 Schiele F, van Ryn J, Canada K. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121 (18) 3554-3562
    CrossrefPubMedGoogle Scholar
  • 110 Na SY, Mracsko E, van Ryn J, Veltkamp R. Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol 2015; 78 (01) 137-141
    CrossrefPubMedGoogle Scholar
  • 111 Grottke O, Honickel M, van Ryn J. et al. Dabigatran-induced anticoagulant and bleeding effects can be reversed with both prothrombin complex concentrates and a specific antidote (idarucizumab) in a lethal porcine polytrauma model. Crit Care 2014; 18 (01) R27
    CrossrefPubMedGoogle Scholar
  • 112 Glund S, Stangier J, Schmohl M. et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014; 124 (21) 344
    CrossrefPubMedGoogle Scholar
  • 113 Pollack Jr CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 114 Pollack Jr CV, Reilly PA, van Ryn J. et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
    CrossrefPubMedGoogle Scholar
  • 115 Abdulrehman J, Zarabi S, Elbaz C. et al. Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals. Res Pract Thromb Haemost 2021; 5 (05) e12535
    CrossrefPubMedGoogle Scholar
  • 116 Fanikos J, Murwin D, Gruenenfelder F. et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. Thromb Haemost 2020; 120 (01) 27-35
    Article in Thieme ConnectPubMedGoogle Scholar
  • 117 Ebinger J, Granger CB, Zhu A, Chang A, Henry TD. Idarucizumab since FDA approval: use in the real-world. Am Heart J 2017; 193: 93-94
    CrossrefPubMedGoogle Scholar
  • 118 Vosko MR, Bocksrucker C, Drwiła R. et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis 2017; 43 (03) 306-317
    CrossrefPubMedGoogle Scholar
  • 119 Brennan Y, Favaloro EJ, Pasalic L, Keenan H, Curnow J. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Intern Med J 2019; 49 (01) 59-65
    CrossrefPubMedGoogle Scholar
  • 120 van der Wall SJ, van Rein N, van den Bemt B. et al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace 2019; 21 (03) 414-420
    CrossrefPubMedGoogle Scholar
  • 121 Glund S, Stangier J, van Ryn J. et al. Restarting dabigatran etexilate 24h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers. J Am Coll Cardiol 2016; 67 (13) 1654-1656
    CrossrefPubMedGoogle Scholar
  • 122 Witt DM, Nieuwlaat R, Clark NP. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2 (22) 3257-3291
    CrossrefPubMedGoogle Scholar
  • 123 Stone GW, Witzenbichler B, Guagliumi G. et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21) 2218-2230
    CrossrefPubMedGoogle Scholar
  • 124 White H. Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358 (9296): 1855-1863
    CrossrefPubMedGoogle Scholar
  • 125 Stone GW, McLaurin BT, Cox DA. et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21) 2203-2216
    CrossrefPubMedGoogle Scholar
  • 126 Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26 (04) 461-468
    CrossrefPubMedGoogle Scholar
  • 127 Berlioz B, Kaseer HS, Sanghavi DK, Guru PK. Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban. BMJ Case Rep 2020; 13 (01) e232262
    CrossrefPubMedGoogle Scholar
  • 128 Koster A, Dyke CM, Aldea G. et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83 (02) 572-577
    CrossrefPubMedGoogle Scholar
  • 129 Bangalore S, Cohen DJ, Kleiman NS. et al; EVENT Registry Investigators, Boston, MA. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ Cardiovasc Interv 2011; 4 (05) 463-473
    CrossrefPubMedGoogle Scholar
  • 130 Ahmad Hamdi AH, Dali AF, Mat Nuri TH. et al. Safety and effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Front Pharmacol 2017; 8: 410
    CrossrefPubMedGoogle Scholar
  • 131 Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 2010; 8 (12) 1673-1681
    CrossrefPubMedGoogle Scholar
  • 132 Mann MJ, Tseng E, Ratcliffe M. et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005; 24 (02) 222-225
    CrossrefPubMedGoogle Scholar
  • 133 Zucker ML, Koster A, Prats J, Laduca FM. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol 2005; 37 (04) 364-368
    CrossrefPubMedGoogle Scholar
  • 134 Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83 (05) 1510-1518
    CrossrefPubMedGoogle Scholar
  • 135 Rieg AD, Grottke O, Schälte G. et al. Recombinant factor VIIa as a reversal agent of the direct thrombin inhibitor argatroban. Chirurgia (Turin) 2011; 24 (05) 283-286
    PubMedGoogle Scholar
  • 136 Muralidharan-Chari V, Mousa SA. Ciraparantag. Heparin neutralizer, anticoagulant reversal agent. Drugs Future 2016; 41 (06) 341
    CrossrefPubMedGoogle Scholar
  • 137 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 138 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    Google Scholar
  • 139 Abraham NS, Singh S, Alexander GC. et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857
    CrossrefPubMedGoogle Scholar
  • 140 Sherid M, Sulaiman S, Samo S. et al. Risk of gastrointestinal bleeding with rivaroxaban: a comparative study with warfarin. Gastroenterol Res Pract 2016; 2016: 9589036
    CrossrefPubMedGoogle Scholar
  • 141 Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2019; 58 (10) 1265-1279
    CrossrefPubMedGoogle Scholar
  • 142 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    Google Scholar
  • 143 Bahit MC, Lopes RD, Wojdyla DM. et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2017; 103 (08) 623-628
    CrossrefPubMedGoogle Scholar
  • 144 Adeboyeje G, Sylwestrzak G, Barron JJ. et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2017; 23 (09) 968-978
    PubMedGoogle Scholar
  • 145 Lip GYH, Keshishian AV, Zhang Y. et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Netw Open 2021; 4 (08) e2120064-e2120064
    CrossrefPubMedGoogle Scholar
  • 146 Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature. Eur J Haematol 2019; 102 (04) 312-318
    CrossrefPubMedGoogle Scholar
  • 147 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    Google Scholar
  • 148 Aisenberg J, Chatterjee-Murphy P, Friedman Flack K. et al. Gastrointestinal bleeding with edoxaban versus warfarin. Circ Cardiovasc Qual Outcomes 2018; 11 (05) e003998
    CrossrefPubMedGoogle Scholar
  • 149 Parasrampuria DA, Marbury T, Matsushima N. et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 2015; 113 (04) 719-727
    Article in Thieme ConnectPubMedGoogle Scholar
  • 150 Exner T, Ahuja M, Ellwood L. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants. Clin Chem Lab Med 2019; 57 (05) 690-696
    CrossrefPubMedGoogle Scholar
  • 151 Godier A, Miclot A, Le Bonniec B. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116 (01) 94-102
    CrossrefPubMedGoogle Scholar
  • 152 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110 (01) 162-172
    PubMedGoogle Scholar
  • 153 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44 (03) 771-778
    CrossrefPubMedGoogle Scholar
  • 154 Herzog E, Kaspereit F, Krege W. et al. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding. Thromb Res 2015; 135 (03) 554-560
    CrossrefPubMedGoogle Scholar
  • 155 Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJM, Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost 2013; 11 (06) 1111-1118
    CrossrefPubMedGoogle Scholar
  • 156 Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014; 133 (04) 671-681
    CrossrefPubMedGoogle Scholar
  • 157 Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E. et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013; 8 (11) e78696
    CrossrefPubMedGoogle Scholar
  • 158 Schenk B, Würtinger P, Streif W, Sturm W, Fries D, Bachler M. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay. Br J Anaesth 2016; 117 (05) 583-591
    CrossrefPubMedGoogle Scholar
  • 159 Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thromb J 2017; 15 (01) 6
    CrossrefPubMedGoogle Scholar
  • 160 Levi M, Moore KT, Castillejos CF. et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12 (09) 1428-1436
    CrossrefPubMedGoogle Scholar
  • 161 Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JCM, Middeldorp S. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol 2016; 172 (02) 255-261
    CrossrefPubMedGoogle Scholar
  • 162 Martin AC, Gouin-Thibault I, Siguret V. et al. Multimodal assessment of non-specific hemostatic agents for apixaban reversal. J Thromb Haemost 2015; 13 (03) 426-436
    CrossrefPubMedGoogle Scholar
  • 163 Martin AC, Le Bonniec B, Fischer AM. et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013; 168 (04) 4228-4233
    CrossrefPubMedGoogle Scholar
  • 164 Majeed A, Ågren A, Holmström M. et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130 (15) 1706-1712
    CrossrefPubMedGoogle Scholar
  • 165 Sheikh-Taha M. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate. Intern Emerg Med 2019; 14 (02) 265-269
    CrossrefPubMedGoogle Scholar
  • 166 Castillo R, Chan A, Atallah S. et al. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. J Thromb Thrombolysis 2021; 51 (01) 151-158
    CrossrefPubMedGoogle Scholar
  • 167 Panos NG, Cook AM, John S, Jones GM. Neurocritical Care Society (NCS) Pharmacy Study Group. Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates. Circulation 2020; 141 (21) 1681-1689
    CrossrefPubMedGoogle Scholar
  • 168 Barra ME, Das AS, Hayes BD. et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost 2020; 18 (07) 1637-1647
    CrossrefPubMedGoogle Scholar
  • 169 Schulman S, Gross PL, Ritchie B. et al; Study Investigators. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost 2018; 118 (05) 842-851
    Article in Thieme ConnectPubMedGoogle Scholar
  • 170 Sheikh-Taha M, Crawley RM. Reversal of apixaban and rivaroxaban using activated prothrombin complex concentrates in patients with major bleeding. Am J Cardiovasc Drugs 2020; 20 (03) 295-299
    CrossrefPubMedGoogle Scholar
  • 171 Barzilai M, Kirgner I, Steimatzky A. et al. Prothrombin complex concentrate before urgent surgery in patients treated with rivaroxaban and apixaban. Acta Haematol 2020; 143 (03) 266-271
    CrossrefPubMedGoogle Scholar
  • 172 Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107 (02) 253-259
    Article in Thieme ConnectPubMedGoogle Scholar
  • 173 Herzog E, Kaspereit F, Krege W. et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology 2015; 122 (02) 387-398
    CrossrefPubMedGoogle Scholar
  • 174 Halim AB, Samama MM, Mendell J. Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res 2014; 134 (04) 909-913
    CrossrefPubMedGoogle Scholar
  • 175 Brown KS, Wickremasingha P, Parasrampuria DA. et al. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thromb Res 2015; 136 (04) 825-831
    CrossrefPubMedGoogle Scholar
  • 176 Zahir H, Brown KS, Vandell AG. et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131 (01) 82-90
    CrossrefPubMedGoogle Scholar
  • 177 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
    CrossrefPubMedGoogle Scholar
  • 178 Lu G, Hollenbach SJ, Baker DC. et al. Preclinical safety and efficacy of andexanet alfa in animal models. J Thromb Haemost 2017; 15 (09) 1747-1756
    CrossrefPubMedGoogle Scholar
  • 179 Lu G, Pine P, Leeds JM. et al. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. PLoS One 2018; 13 (03) e0195122
    CrossrefPubMedGoogle Scholar
  • 180 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
    CrossrefPubMedGoogle Scholar
  • 181 Connolly SJ, Milling Jr TJ, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa Iihibitors. N Engl J Med 2016; 375 (12) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 182 Demchuk AM, Yue P, Zotova E. et al; ANNEXA-4 Investigators. Hemostatic efficacy and anti-FXa (Factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 Substudy. Stroke 2021; 52 (06) 2096-2105
    CrossrefPubMedGoogle Scholar
  • 183 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
    CrossrefPubMedGoogle Scholar
  • 184 Siegal D, Beyer-Westendorf J, Yue P. et al. The efficacy and safety of andexanet alfa in patients with acute gastrointestinal bleeding while taking factor Xa inhibitors: an ANNEXA-4 sub-analysis. Am J Gast. 2019; 114: S332-S333
    CrossrefPubMedGoogle Scholar
  • 185 Coppens M, Xu L, Bavalia R. et al. Effects of andexanet alfa on thrombin generation in bleeding associated with factor Xa inhibitors. Blood 2019; 134: 711
    CrossrefPubMedGoogle Scholar
  • 186 Ice C, Gurka M, Parker J, Hunt A. Feiba and andexant alfa for the reversal in uncontrolled hemorrhage. Crit Care Med 2022; 50 (01) 449
    CrossrefPubMedGoogle Scholar
  • 187 Stevens VM, Trujillo TC, Kiser TH, MacLaren R, eynolds PM, Mueller SW. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clin Appl Thromb Hemost 2021; 27: 107602962 11039020
    CrossrefPubMedGoogle Scholar
  • 188 Lu G, Conley PB, Leeds JM. et al. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv 2020; 4 (04) 728-739
    CrossrefPubMedGoogle Scholar
  • 189 Crowther M, Levy GG, Lu G. et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet Alfa PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 2014; 124 (21) 4269
    CrossrefPubMedGoogle Scholar
  • 190 Benz AP, Xu L, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban. Thromb Haemost 2022; 122 (06) 998-1005
    Article in Thieme ConnectPubMedGoogle Scholar
  • 191 Bakhru S, Laulicht B, Jiang X. et al. PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation 2013; 128 (Suppl. 22) A18809-A18809
    PubMedGoogle Scholar
  • 192 Hollenbach S, Lu G, DeGuzman F. et al. Andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model - Only andexanet reverses markers of fXa-mediated anticoagulation. Circulation 2014; 130 (Suppl. 02) A14657-A14657
    PubMedGoogle Scholar
  • 193 Ansell J, Bakhru S, Laulicht BE, Tracey G, Villano S, Freedman D. Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. Eur Heart J 2022; 43 (10) 985-992
    CrossrefPubMedGoogle Scholar